Diagnosis and Therapy of Brain Tumors Utilizing Radiolabeled Monoclonal Antibodies
Monoclonal antibodies (MAbs) have been developed against a wide variety of tumor-associated antigens and normal tissue antigens, including receptor molecules, extracellular matrix proteins, enzymes, and hormones. The in vitro use of these MAbs has greatly improved our ability to diagnose a number of diseases, including many cancers. The extension of MAbs to in vivo diagnosis and therapy, as the “magic bullets” envisioned by Paul Ehrlich1 at the turn of the century, has, however, met with more limited success. There are a number of reasons for this, and currently there is a great effort underway, using animal models to solve these problems, to pave the way for clinical use of MAbs in patients. To illustrate the problems inherent in the development of radiolabeled MAbs for clinical use, we will present our work utilizing MAbs in a variety of brain tumor models.
KeywordsEpidermal Growth Factor Receptor Mutant Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Gene Athymic Mouse Human Tumor Xenograft
Unable to display preview. Download preview PDF.
- 1.P. Ehrlich, Collected Studies on Immunology, Wiley, New York (1906).Google Scholar
- 5.R. Virchow, Die krankhalten Geschwuelste, A. Hirshwald, Berlin, (11).Google Scholar
- 20.D. Colcher, J. Esteban, J. A. Carrasquillo, P. Sugarbaker, J. C. Reynolds, G. Bryant, S. M. Larson, and J. Schlom, Comparison of route of administration of radiolabeled monoclonal antibodies in patients with colorectal cancer, J. Nucl. Med. 27:(Abst) 902 (1986).Google Scholar
- 23.M. R. Zalutsky, R. P. Moseley, J. C. Benjamin, E. V. Colapinto, G. N. Fuller, H. P. Coakham, and D. D. Bigner, Monoclonal antibody and F(ab’)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration, Cancer Res. 50:4105 (1990).PubMedGoogle Scholar
- 24.R. Moseley, M. R. Zalutsky, H. B. Coakham, R. E. Coleman, and D. D. Bigner, Distribution of 131I-8lC6 monoclonal antibody (MAb) administered via carotid artery in patients with glioma, J. Nucl. Med. 28:603-604 (1987).Google Scholar
- 27.H. E. Fuchs, G. E. Archer, O. M. Colvin, S. H. Bigner, J. M. Schuster, G. N. Fuller, L. H. Muhlbaier, S. C. Schold, H. S. Friedman, and D. D. Bigner, Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis, Cancer Res. 50:1954 (1990).PubMedGoogle Scholar
- 28.M. R. Zalutsky, P. K. Garg, J. M. Schuster, H. E. Fuchs, G. E. Archer, S. Garg, and D. D. Bigner, Radioimmunotherapy of leptomeningeal tumor using AT-211 monoclonal antibody. 9th International Congress of Radiation Research. Radiat. Res., in press (1991).Google Scholar
- 30.R. P. Moseley, A. B. Davies, R. B. Richardson, M. Zalutsky, S. Carrel, J. Fabre, N. Slack, J. Bullimore, B. Pizer, V. Papanastassiou, J. T. Kemshead, H. B. Coakham, and L. S. Lashford, Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis, Br. J. Cancer 62:637 (1990).PubMedCrossRefGoogle Scholar
- 31.P. A. Humphrey, A. J. Wong, B. Vogelstein, M. R. Zalutsky, G. N. Fuller, G. E. Archer, H. S. Friedman, M. M. Kwatra, S. H. Bigner, and D. D. Bigner, Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma, Proc. Natl. Acad. Sci. USA, 87:4207 (1990).PubMedCrossRefGoogle Scholar